Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States
Journal of Managed Care & Specialty Pharmacy | September 9, 2024 | Volume: 30 | Issue: 12 | Pages: 1431-1441
10.18553/jmcp.2024.24085
| PMID 39612251